Becker's Healthcare January 14, 2025
AbbVie will write off $3.5 billion related to its $8.7 billion investment in Cerevel Therapeutics following the failure of the company’s key schizophrenia drug, emraclidine, The Wall Street Journal reported Jan. 10.
The write down comes after emraclidine missed crucial goals in two mid-stage trials, prompting AbbVie to reassess the drug’s value. In November, the company revealed that the drug failed to meet...